ArticleFrontiers in pharmacology2026
Rhabdomyolysis secondary to chlorpheniramine maleate toxicity: a case report.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chlorpheniramine maleate is a commonly used antiallergic drug; excessive ingestion can cause adverse effects such as hallucinations, tachycardia, central nervous system depression, and organ dysfunction. However, rhabdomyolysis induced by this drug is rarely reported. This study presents a case of rhabdomyolysis secondary to chlorpheniramine maleate poisoning. Case Report: A 14-year-old female student developed palpitations after oral ingestion of 100 tablets of chlorpheniramine maleate (4 mg per tablet). Six hours post-ingestion, laboratory tests showed elevated concentrations of myoglobin (>1,200 ng/mL) and creatine kinase (1529.7 U/L). Nine hours post-ingestion, the myoglobin concentration gradually decreased to 889 ng/mL, while the creatine kinase concentration continued to rise to 7,315 U/L. One day after ingestion, the myoglobin concentration further decreased, whereas the creatine kinase concentration peaked at 11,219 U/L. Indicators including troponin, creatine kinase-MB mass, serum creatinine, and serum uric acid remained within the normal range. Following treatment with gastrointestinal decontamination, diuresis, and maintenance of electrolyte balance, the patient's condition improved and she was discharged. Discussion: Chlorpheniramine maleate poisoning can cause hallucinations, hypertension, tachycardia, organ dysfunction, and central nervous system depression. Additionally, it may be a potential etiological factor for rhabdomyolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.